Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Launched by UNIVERSITY OF ROMA LA SAPIENZA · Jul 3, 2020

Keywords

ClinConnect Summary

The REBORN trial is a study looking at new ways to diagnose and monitor the treatment of neuroendocrine tumors (NENs), which are a type of cancer that can arise from hormone-producing cells. Researchers are exploring new markers in the blood that could help identify these tumors earlier and evaluate how well treatments are working. This study is taking place at multiple centers and is currently recruiting participants who are between the ages of 65 and 74, as well as younger individuals, regardless of gender.

To be eligible for the trial, participants must have a confirmed diagnosis of neuroendocrine tumors that are either locally advanced or have spread to other parts of the body and are about to start their first treatment. Additionally, patients with certain non-cancerous endocrine diseases may also participate as part of a control group. Those with severe kidney disease or significant problems with their lungs, heart, or liver will not be able to join the study. Participants can expect to undergo assessments that will help researchers learn more about how these new biomarkers can improve the diagnosis and treatment of NENs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);
• • Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).
• Exclusion Criteria:
• • Severe chronic kidney disease (stage 4-5);
• • Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;
• • Other non-neuroendocrine malignancies.